MBOT צמיחה צפויה ברווח נקי למניה השנה microbotmedical.com

Microbot Medical Inc. (MBOT) faces a lack of stable revenue and regulatory risks. The annual EPS growth metric on the GURU.Markets chart visualizes these challenges, where the -5.20 level captures the current state. The company is developing minimally invasive robotics for clinics, yet the project's success depends on FDA approval and strict control of R&D costs.

For Microbot Medical Inc. (MBOT), high R&D expenditures and regulatory risks make achieving profitability dependent on the approval of its robot in the US. This metric measures the annual change in earnings per share, reflecting the business's ability to generate net income relative to the previous period, which allows the annual EPS trend to assess the market consensus on capital management efficiency and inflationary risks.